2. The drug behind Europe's most valuable company

2. The drug behind Europe's most valuable com...

Up next

294. Gary Stevenson – Is being a city trader bad?

Is it fair that city traders can make loads of money betting on the economy’s demise? Are people with working class backgrounds better at trading? How do you go from making millions on a trade floor to becoming obsessed with wealth inequality? In the first of our two-part series, ...  Show more

293. A Nobel Prize winning view on wealth inequality

Why are some countries richer than others, even though money, people and ideas can flow freely round the world? Why is it so hard for a country to turn things around and become rich? Are illiberal leaders like Trump good for their economy? What role do sovereign wealth funds play ...  Show more

Recommended Episodes

068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond
Tomorrow – A podcast by Allianz Research

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

The Dark Story Behind Ozempic’s $500B Business Empire
My First Million

Episode 601: Sam Parr ( https://twitter.com/theSamParr ) and Shaan Puri ( https://twitter.com/ShaanVP ) talk to Calley Means ( https://x.com/calleymeans ) about the $50T drug that has Americans in a chokehold.  — Show Notes: (0:00) Intro  (1:54) The problem with Ozempic (4:25) A ...  Show more

Money Talks: Why weight-loss drugs will reshape the world
Money Talks from The Economist

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ...

  Show more

Money Talks: Why weight-loss drugs will reshape the world
Economist Podcasts

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ...  Show more